Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedJun 20, 2026
DataAggregated Company Financials
Companies550
  • 7D1.3%
  • 3M3.5%
  • 1Y31.4%
  • YTD2.5%

The Biotech industry is up 1.3% in the last week, with Moderna up 28%. This takes the industry's 12 month performance to a gain of 31%. Earnings are forecast to grow by 25% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 20 Jun 2026US$1.3tUS$170.0b-US$12,150,587,399.2116.5x-107x7.6x
Mon, 18 May 2026US$1.3tUS$170.3b-US$12,626,410,453.0017.2x-101.1x7.5x
Wed, 15 Apr 2026US$1.3tUS$166.2b-US$11,979,538,921.9217.5x-109.3x7.9x
Fri, 13 Mar 2026US$1.3tUS$169.1b-US$15,394,683,526.0221.1x-86.5x7.9x
Sun, 08 Feb 2026US$1.3tUS$164.5b-US$14,975,001,086.6922.8x-87.2x7.9x
Tue, 06 Jan 2026US$1.2tUS$163.5b-US$15,346,868,253.5721.1x-78x7.3x
Thu, 04 Dec 2025US$1.2tUS$163.6b-US$16,190,681,448.1419.6x-76x7.5x
Sat, 01 Nov 2025US$1.1tUS$162.2b-US$16,412,994,842.2417.7x-68.5x6.9x
Mon, 29 Sep 2025US$1.1tUS$163.5b-US$18,298,125,619.8316.3x-58.9x6.6x
Wed, 27 Aug 2025US$1.1tUS$163.6b-US$18,630,807,213.6115.3x-56.5x6.4x
Fri, 25 Jul 2025US$997.5bUS$155.2b-US$23,161,447,469.4316.9x-43.1x6.4x
Sun, 22 Jun 2025US$930.4bUS$155.9b-US$23,931,619,289.3716.8x-38.9x6x
Tue, 20 May 2025US$895.3bUS$155.9b-US$24,383,038,329.0316.1x-36.7x5.7x
Thu, 17 Apr 2025US$763.1bUS$119.2b-US$36,649,632,928.0519.4x-20.8x6.4x
Sat, 15 Mar 2025US$834.3bUS$118.4b-US$37,624,196,989.9318.5x-22.2x7x
Mon, 10 Feb 2025US$840.3bUS$117.3b-US$30,891,273,158.0417.2x-27.2x7.2x
Wed, 08 Jan 2025US$967.5bUS$149.6b-US$26,358,490,111.7216.5x-36.7x6.5x
Fri, 06 Dec 2024US$1.0tUS$150.0b-US$26,562,709,685.0617.5x-38.7x6.9x
Sun, 03 Nov 2024US$1.1tUS$147.4b-US$30,522,373,860.5217.5x-35x7.2x
Tue, 01 Oct 2024US$894.5bUS$113.2b-US$36,002,779,251.2421.3x-24.8x7.9x
Thu, 29 Aug 2024US$907.1bUS$113.1b-US$35,726,620,298.3524.2x-25.4x8x
Sat, 27 Jul 2024US$1.2tUS$164.9b-US$28,965,808,648.7626.4x-42.6x7.5x
Mon, 24 Jun 2024US$1.2tUS$164.4b-US$27,942,490,934.1228.1x-41.4x7x
Wed, 22 May 2024US$1.1tUS$164.6b-US$26,765,333,205.6424.5x-42.8x7x
Fri, 19 Apr 2024US$1.1tUS$164.2b-US$23,337,120,518.7320.4x-45.9x6.5x
Sun, 17 Mar 2024US$1.2tUS$167.4b-US$22,071,849,383.6413.9x-53.2x7x
Tue, 13 Feb 2024US$1.2tUS$169.3b-US$26,222,327,301.1520.4x-44.5x6.9x
Thu, 11 Jan 2024US$1.4tUS$204.8b-US$22,494,732,823.0019.3x-64.2x7.1x
Sat, 09 Dec 2023US$1.3tUS$204.6b-US$22,091,414,218.0018.7x-58.4x6.3x
Mon, 06 Nov 2023US$1.2tUS$206.7b-US$20,529,146,956.0018.8x-60.5x6x
Wed, 04 Oct 2023US$1.2tUS$207.3b-US$13,085,561,707.0016.6x-94.9x6x
Fri, 01 Sep 2023US$1.3tUS$207.6b-US$12,418,173,316.0017.4x-103.3x6.2x
Sun, 30 Jul 2023US$1.1tUS$186.0b-US$15,177,418,533.0014.7x-74.9x6.1x
Tue, 27 Jun 2023US$1.1tUS$186.2b-US$16,151,917,994.0013.4x-69.8x6.1x
Price to Earnings Ratio

-69.8x


Total Market Cap: US$1.1tTotal Earnings: -US$16,151,917,994.00Total Revenue: US$186.2bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -58.5x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.9x is lower than the industry's current PS ratio of 7.6x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 3.0% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market1.40%
Healthcare-1.82%
Biotech1.34%
Biotech1.34%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MRNA ModernaUS$63.9628.2%
+US$5.6b		146.9%PS11.4x
NTRA NateraUS$231.419.1%
+US$2.8b		34.7%PS13.3x
RVMD Revolution MedicinesUS$162.995.9%
+US$1.9b		311.0%PB23.1x
VRTX Vertex PharmaceuticalsUS$451.631.5%
+US$1.7b		2.4%PE26.4x
QURE uniQureUS$46.2967.9%
+US$1.2b		225.8%PS161.4x

Latest News

QURE
US$46.29
uniQure
7D
67.9%
1Y
225.8%
Analysis Article • 52m

uniQure (QURE) Stock Could Be 12% Undervalued After FDA Backs AMT 130 Filing Path

uniQure (NasdaqGS:QURE) is back in focus after the FDA said three year Phase I/II data for its Huntington’s disease gene therapy, AMT-130, can underpin a Biologics License Application for accelerated approval. See our latest analysis for uniQure. The FDA update has arrived after a sharp reset in sentiment around uniQure, with the stock posting a 90 day share price return of 187.69% and a 1 year total shareholder return of 225.76%. This points to strong positive momentum from a much lower...
ARWR
US$81.82
Arrowhead Pharmaceuticals
7D
9.8%
1Y
434.1%
Analysis Article • 7h

Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update

Arrowhead Pharmaceuticals (ARWR) recently outlined a Summer Series of R&D webinars focused on its cardiometabolic pipeline, alongside positive clinical updates and upcoming regulatory milestones that have drawn fresh attention to the stock. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ recent R&D webinar announcement and positive late May clinical readouts have coincided with strong momentum, including a 45.25% 3 month share price return and a very large 1...
NTRA
US$231.41
Natera
7D
9.1%
1Y
34.7%
Analysis Article • 10h

Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data

Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...
ABBV
US$216.49
AbbVie
7D
-4.9%
1Y
16.8%
Seeking Alpha • Jun 19

AbbVie: Immunology Cash Flow Funds Oncology Expansion

Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking Alpha
ROIV
US$31.43
Roivant Sciences
7D
4.6%
1Y
174.5%
Analysis Article • Jun 19

Roivant Sciences (ROIV) Stock Could Be 19.5% Undervalued After Moderna Settlement And Pipeline Progress

Roivant Sciences (ROIV) has drawn fresh attention after announcing a US$2.25b global settlement with Moderna that ends ongoing patent litigation, along with positive IMVT-1402 rheumatoid arthritis data and Breakthrough Therapy Designation for brepocitinib. See our latest analysis for Roivant Sciences. At a share price of US$31.43, Roivant Sciences has seen a 4.63% 7 day share price return and a 13.47% 90 day share price return. Its 1 year total shareholder return of 174.50% and 3 year total...
LEGN
US$27.93
Legend Biotech
7D
-22.1%
1Y
-17.9%
CYTK
US$78.78
Cytokinetics
7D
12.3%
1Y
142.9%
Analysis Article • Jun 19

Cytokinetics (CYTK) Stock Could Be 15% Undervalued After Myqorzo Approval

Cytokinetics (CYTK) is back in focus after the FDA cleared its first commercial product, Myqorzo, for symptomatic obstructive hypertrophic cardiomyopathy, with early launch data and European approvals drawing fresh attention to the stock. See our latest analysis for Cytokinetics. Against this backdrop, Cytokinetics' short term share price momentum has been strong, with a 7 day share price return of 13.73% and a 90 day share price return of 27.68%. Its 1 year total shareholder return of...
BIIB
US$196.58
Biogen
7D
-1.7%
1Y
54.7%
MRNA
US$63.96
Moderna
7D
28.2%
1Y
146.9%
INCY
US$98.22
Incyte
7D
-9.5%
1Y
43.5%
Analysis Article • Jun 17

Incyte (INCY) Stock Could Be 8.1% Undervalued After FDA Priority Review And Trial Results

Recent interest in Incyte (INCY) stock is closely tied to fresh clinical and regulatory milestones, including pivotal data for zilurgisertib in fibrodysplasia ossificans progressiva and Phase 3 results for tafasitamab plus lenalidomide with R-CHOP. See our latest analysis for Incyte. Incyte stock has cooled slightly in the very short term, with a 1-day share price return of 2.19% and a 7-day share price return of 5.35%. However, the 1-year total shareholder return of 46.11% and 3-year total...
AMGN
US$337.60
Amgen
7D
-5.0%
1Y
16.7%
VRTX
US$451.63
Vertex Pharmaceuticals
7D
1.5%
1Y
2.4%
Narrative Update • Jun 17

VRTX: Kidney Franchise And Pipeline Expansion Will Drive Future Stock Upside

Vertex Pharmaceuticals' latest narrative update reflects a modest recalibration in analyst price targets, with figures such as Truist's move to $542 and Wells Fargo's lift to $550 framed around analysts' view that the emerging kidney franchise can grow into blockbuster assets and broaden the company's portfolio. Analyst Commentary Recent Street research on Vertex Pharmaceuticals highlights a generally constructive tone, with bullish analysts pointing to the expanding kidney franchise and a series of upward price target revisions as key supports for the stock's valuation and growth narrative.
INSM
US$95.80
Insmed
7D
-2.1%
1Y
-6.7%
Narrative Update • Jun 16

INSM: 2026 Respiratory Launch Execution Will Drive Bronchiectasis Upside Debate

Insmed's updated analyst price target edges down slightly to about $197, with analysts citing refined Brinsupri revenue, margin and P/E assumptions. They still point to recent share weakness and Q2 uncertainty as key factors in their revised, but broadly constructive, models.
RVMD
US$162.99
Revolution Medicines
7D
5.9%
1Y
311.0%
ALNY
US$278.09
Alnylam Pharmaceuticals
7D
-1.7%
1Y
-10.2%
Narrative Update • Jun 16

ALNY: TTR Franchise Execution And 2030 Plan Will Support Stock Repricing

The analyst price target for Alnylam Pharmaceuticals has been adjusted to $550. This move reflects updated views on fair value, growth assumptions, and profitability, while aligning with recent Street commentary that highlights both the pullback in the stock and ongoing expectations around Amvuttra's launch and competitive pressures.
GILD
US$123.76
Gilead Sciences
7D
-1.5%
1Y
14.1%